Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks tumbled Tuesday on hotter-than-expected retail inflation data. The surprise uptick within the January consumer price index sent bond yields higher and the Dow , the S & P 500 and the Nasdaq all down more than 1% each. Frankly, we’re not surprised to see the pullback in equities since the market has been up 14 out of the past 15 weeks. The brand new CPI data put market expectations around rate of interest cuts more in keeping with the Federal Reserve’s commentary. Excellent news for the Club: We’ve a big money position. This dip if it were to proceed could present one other buying opportunity. Nevertheless, we’re staying patient for now. 2. Wall Street continued singing the praises of Palo Alto Networks . Jefferies analysts raised the cybersecurity name’s price goal to $450 per share from $350. Stifel analysts boosted theirs to $410 from $280. Research analysts at each firms cited strong channel checks ahead the cybersecurity leader’s quarter earnings release next week. Jefferies said the largest risk on Palo Alto immediately is its 29% year-to-date gains, which far outpace the S & P 500’s roughly 4% increase. The stock more than doubled in 2023. Like analysts overall, we think Palo Alto has an important setup for the yr, given the surging demand for cybersecurity offerings. 3. Jefferies boosted Eli Lilly’s price goal to $853 per share from $815. The analysts are growing more confident in the security profile of orforglipron, the corporate’s GLP-1 weight reduction/diabetes pill going through the drug trial process. That is critical to its business future because Pfizer discontinued one in every of its experimental GLP-1 pills resulting from toxicity issues last yr. Alongside quarterly earnings, Eli Lilly said it plans to construct supply of orforglipron ahead of approval since it sees such a powerful opportunity. We’re bullish on this because the corporate has a track record of constructing the suitable calls — each by way of efficacy and safety. If Lilly shares weren’t climbing higher in Tuesday’s down market, we would consider buying more, given the solid fundamentals and serious growth prospects. The leading GLP-1s available on the market — Lilly’s Zepbound and Mounjaro, and Novo Nordisk ‘s Ozempic and Wegovy — are injectables (Jim Cramer’s Charitable Trust is long PANW, LLY. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you’ll receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked a couple of stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.